Damian Garnet, Sonic AI

Skip to content

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Damian Garnet, Sonic AI

Home/Library/Damian Garnet

D

Damian Garnet

Person

13

Mentions

1

Episodes

13

Claims

Damian Garnet, mentioned 13 times across podcast episodes and expert conversations analyzed by Sonic.

What Damian Garnet has said

The Federal Trade Commission under the Biden administration is adopting a new approach to regulating antitrust and policing mergers.

neutral·Damian Garnet

Pfizer's 2024 financial guidance for revenue and profits was far below analysts' expectations.

bearish·Damian Garnet

Both Eli Lilly and Novo Nordisk have recently acquired companies with potentially competing obesity drugs without facing an FTC challenge.

neutral·Damian Garnet

The Federal Trade Commission under the Biden administration is adopting a new approach to regulating antitrust and policing mergers.

Expert perspectiveDamian GarnetApr 20

Pfizer's 2024 financial guidance for revenue and profits was far below analysts' expectations.

Expert perspectiveDamian GarnetApr 20

Both Eli Lilly and Novo Nordisk have recently acquired companies with potentially competing obesity drugs without facing an FTC challenge.

Expert perspectiveDamian GarnetApr 20

The mechanism of Vertex's pain drug is inspired by rare human genetic mutations that cause some individuals to feel no pain.

Expert perspectiveDamian GarnetApr 20

Pfizer projects its COVID-19 vaccine and treatment will generate $8 billion in revenue for 2024.

Expert perspectiveDamian GarnetApr 20

Sanofi announced it was terminating its licensing deal with Maize Therapeutics within an hour of the FTC's challenge being made public.

Expert perspectiveDamian GarnetApr 20

Pfizer's stock price has declined approximately 50% since the start of 2023.

Expert perspectiveDamian GarnetApr 20

The Federal Trade Commission previously challenged Amgen's acquisition of Horizon Pharmaceuticals.

Expert perspectiveDamian GarnetApr 20

The FTC's complaint against Sanofi suggests that a review of internal documents led the agency to conclude Sanofi intended to kill or slow the development of the licensed drug from Maize Therapeutics.

Expert perspectiveDamian GarnetApr 20

The recent rise in the XBI biotech index was tied to a Federal Reserve meeting where Chairman Jerome Powell indicated no further rate hikes and potential rate cuts in 2024.

Expert perspectiveDamian GarnetApr 20

As of mid-December 2023, the XBI biotech index is up for the year after being down by more than 20% as recently as October.

Expert perspectiveDamian GarnetApr 20

The FTC alleged that Sanofi was licensing a drug from Maize Therapeutics to slow its development or kill it, thereby maintaining its own monopoly in the Pompe disease market.

Expert perspectiveDamian GarnetApr 20

Maize Therapeutics learned that its partner Sanofi was terminating their licensing deal from Sanofi's public press release.

Expert perspectiveDamian GarnetApr 20

Create a free account to see Damian Garnet's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail